Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis.
Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis.
复制标题
DOI：
10.1371/journal.pone.0176972
复制
发表时间：
2017
期刊：
影响因子：
3.7
通讯作者：
Ishioka C
中科院分区：
文献类型：
--
作者：
Takahashi M;Komine K;Imai H;Okada Y;Saijo K;Takahashi M;Shirota H;Ohori H;Takahashi S;Chiba N;Mori T;Shimodaira H;Ishioka C
据报道，吉西他滨和多西他赛联合治疗是软组织肉瘤患者的良好治疗策略。本研究的目的是分析吉西他滨联合多西他赛治疗晚期骨和软组织肉瘤日本患者的疗效和毒性。我们回顾性分析了2006年10月至2015年9月在东北大学附属医院接受吉西他滨和多西他赛治疗的42例骨或软组织肉瘤患者的总缓解、无进展生存期、总生存期和毒性的影响。中位年龄为55岁; 23例患者为男性，19例为女性。骨肉瘤8例，软组织肉瘤34例。40例患者（95%）既往接受过一种或多种化疗方案治疗。总有效率为6.9%，疾病控制率为55%。中位无进展生存期为2.3个月，中位总生存期为14.3个月。分别在74%和4.8%的所有患者中观察到3级或以上中性粒细胞减少和发热性中性粒细胞减少。与其他既往报告相比，缓解率较低，骨髓抑制更常见。另一方面，大多数毒性是足够可控的。此外，部分患者生存期长，反应良好。我们的研究支持这样的观点，即吉西他滨和多西他赛治疗是治疗晚期软组织肉瘤和骨肉瘤患者的良好治疗选择，也适用于亚洲人群。
Combination therapy with gemcitabine and docetaxel has been reported to be a good therapeutic strategy for patients with soft tissue sarcoma. The aim of the present study was to analyze the efficacy and toxicity of gemcitabine with docetaxel in Japanese patients with advanced bone and soft tissue sarcoma. We retrospectively analyzed the effect of gemcitabine and docetaxel therapy on overall response, progression-free survival, overall survival, and toxicity in 42 patients with bone or soft tissue sarcoma who had received the therapy between October 2006 and September 2015, at Tohoku University Hospital. The median age was 55 years; 23 patients were men, and 19 were women. Eight had bone sarcoma and 34 had soft tissue sarcoma. Forty patients (95%) had previously been treated with one or more chemotherapeutic regimens. The overall response rate was 6.9% and the disease control rate was 55%. The median progression-free survival was 2.3 months and the median overall survival was 14.3 months. Grade 3 or more neutropenia and febrile neutropenia were observed in 74% and 4.8% of all patients, respectively. The response rate was lower and myelosuppression was more frequently observed than in other previous reports. On the other hand, most of toxicities were enough manageable. In addition, some patients had long survival with a good response. Our study supports the notion that gemcitabine and docetaxel therapy is a good therapeutic option for treating patients with advanced soft tissue sarcoma as well as bone sarcoma, also in Asian populations.